

Blenrep Dose Modifications for Adverse Reactions

Adverse Reaction	Severity	Dose Modification Recommendations
Corneal Adverse Reactions <i>(Based on the worst finding in the worst affected eye)</i>	Grade 1 <ul style="list-style-type: none"> • Corneal examination findings: mild superficial keratopathy • BCVA change*: decline of 1 line on Snellen Visual Acuity from baseline 	None; continue at current dose.
	Grade 2 <ul style="list-style-type: none"> • Corneal examination findings: moderate superficial keratopathy • BCVA change*: decline of 2 or 3 lines on Snellen Visual Acuity from baseline and not worse than 20/200 	Withhold treatment until improvement observed in corneal examination findings and BCVA change to Grade 1 or better; resume at same dose.
	Grade 3 <ul style="list-style-type: none"> • Corneal examination findings: severe superficial keratopathy • BCVA change*: decline of >3 lines on Snellen Visual Acuity from baseline and not worse than 20/200 	Withhold treatment until improvement observed in corneal examination findings and BCVA change to Grade 1 or better; resume at reduced dose.
	Grade 4 <ul style="list-style-type: none"> • Corneal examination findings: corneal epithelial defect • BCVA change*: Snellen Visual Acuity worse than 20/200 	Permanent discontinuation should be considered. If treatment is continued, withhold until improvement observed in corneal examination findings and BCVA change to Grade 1 or better; resume at reduced dose.
Thrombocytopenia	Platelet count 25,000 to <50,000/mcL	Consider withholding and/or reducing dose.
	Platelet count <25,000/mcL	Withhold treatment until platelet count improves to Grade 3 or better; consider resuming at a reduced dose.
Infusion-Related Reactions	Grade 2 or Grade 3	Stop infusion and initiate supportive care; resume at a reduced infusion rate (≥50% lower than original) once symptoms resolve.
	Grade 4	Discontinue treatment permanently and provide emergency care.
Other Adverse Reactions	Grade 3	Withhold treatment until improvement to Grade 1 or better is observed; consider resuming at reduced dose.
	Grade 4	Permanent discontinuation should be considered. If treatment is continued, withhold until improvement to Grade 1 or better is observed; resume at reduced dose.

BCVA: Best-corrected visual acuity

*change in visual acuity is measured using the Keratopathy and Visual Acuity (KVA) scale